Supportive Care in Cancer最新文献

{"title":"Symptomatic malignant ascites drainage with a patient-controlled vascular catheter: interim analysis of safety and patient-reported outcomes.","authors":"Maciej Stukan, Marcin Jędryka, Andrej Cokan, Jaroslav Klát, Munachiso Iheme Ndukwe, Marcin Kryszpin, Renata Poblocka, Eva Timošek, Martina Romanová, Klára Balcarová, Radoslaw Madry, David Cibula","doi":"10.1007/s00520-025-09265-4","DOIUrl":"https://doi.org/10.1007/s00520-025-09265-4","url":null,"abstract":"<p><p>Malignant ascites (MA) and repeated paracentesis can impair a patient's quality of life (QOL). The aim was to perform an interim analysis of safety and changes in patients' QOL in an ongoing prospective, multicentre (conducted within the Central and Eastern European Gynaecologic Oncology Group (CEEGOG)) trial on symptomatic MA drainage with a patient-controlled central vascular catheter (CVC) inserted into the abdominal cavity. CVC (14-Ga) was inserted into the abdominal cavity of patients with symptomatic MA, and drainage was controlled by patients at home. The rate and quality of complications were classified according to Common Terminology Criteria for Adverse Events Version 5.0. QOL was evaluated before and 10-14 days after/during drainage with standardized QLQ-C15-PAL, SGA, and FACIT-TS-G questionnaires. Wilcoxon and Chi-squared tests were used. Among 113 recruited patients (2015-2022), seven patients experienced complications (6.2%), and there was one patient with a serious adverse event (death on the 9th day after catheter insertion, classified as not related to the intervention). Adverse events included local infection (n = 2) (resolved after oral antibiotics), catheter obstruction (n = 2), catheter self-removal (n = 2) (re-insertion performed), and nausea (n = 1). When comparing the assessment before and after/during drainage, we found the significantly better global QOL (mean 31.8 vs. 47.8, p < 0.001), improvement in physical (52.6 vs. 64.4, p < 0.001) and emotional functioning (50.7 vs. 65.4, p < 0.001); symptoms were significantly less intense: fatigue (66.7 vs. 50.9, p < 0.001), nausea and vomiting (37.8 vs. 21.4, p < 0.001), pain (53.9 vs. 34.1, p < 0.001), dyspnoea (48.5 vs. 22.3, p < 0.001), insomnia (49.1 vs. 34.3, p < 0.001), appetite loss (56.3 vs. 40.3, p < 0.001), and constipation (31.0 vs. 25.2, p = 0.007), and more patients had no pain on eating (71.3% vs. 82.9%, p = 0.04). Most patients (78%) were satisfied, 83% would recommend the procedure to others, and 90% would choose intervention again. The interim analysis provided data on the safety and improvement of patients' QOL after MA drainage via patient-controlled CVC inserted into the abdominal cavity, thus justifying the continuation of recruitment for the main trial without changes in the protocol.</p>","PeriodicalId":22046,"journal":{"name":"Supportive Care in Cancer","volume":"33 3","pages":"202"},"PeriodicalIF":2.8,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143450441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating factors influencing subjective taste and smell alterations in colorectal cancer patients.","authors":"Wenhui Wang, Zhao Li, Xiaomeng Zhang, Yize Li, Shengnan Kong, Bailu Zou, Mengxue Wang, Na Cheng, Hong-Mei Zhang, Juanhua Sun","doi":"10.1007/s00520-025-09267-2","DOIUrl":"https://doi.org/10.1007/s00520-025-09267-2","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to assess the factors influencing self-reported taste and smell disturbances in patients with colorectal cancer.</p><p><strong>Methods: </strong>A total of 152 participants were enrolled in the study. All subjects completed surveys that assessed taste and smell alterations using the Taste and Smell Survey (TSS), linear analog self-assessment (LASA), Patient-Generated Subjective Global Assessment (PG-SGA), and Pittsburgh Sleep Quality Index (PSQI). The TSS gathered data on the nature of taste and smell changes and their impact on quality of life. LASA was employed to evaluate the quality of life in cancer patients, while PG-SGA was used to indicate the nutritional status of the participants. PSQI was used to evaluate sleep quality.</p><p><strong>Results: </strong>Among the 152 colorectal cancer patients, the total TSS score was 5.68 ± 2.84. No changes were observed in 5 cases (3.3%), mild changes in 58 cases (38.2%), and moderate to severe changes in 89 cases (58.6%). The severity of taste and smell disturbances increased with tumor stage, the cycle of chemotherapy, deteriorating sleep quality, and poor nutritional status, displaying significant correlations. Additionally, 83 patients (54.6%) complained of taste abnormalities, while 81 (53.3%) reported smell abnormalities.</p><p><strong>Conclusion: </strong>Taste and smell disturbances are prominent in colorectal cancer patients. Taste abnormalities are significantly correlated with tumor stage, the cycle of chemotherapy, sleep quality, and nutritional status. Recognizing the high prevalence of taste and smell abnormalities and the influencing factors among patients with colorectal cancer may aid in predicting and understanding the severity of these symptoms more effectively.</p>","PeriodicalId":22046,"journal":{"name":"Supportive Care in Cancer","volume":"33 3","pages":"205"},"PeriodicalIF":2.8,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Testing items to screen for religious or spiritual distress in adult outpatient cancer care.","authors":"Dirk Labuschagne, Patricia K Palmer, Teresa Deshields, James Gerhart, George Fitchett","doi":"10.1007/s00520-025-09260-9","DOIUrl":"https://doi.org/10.1007/s00520-025-09260-9","url":null,"abstract":"<p><strong>Purpose: </strong>The experience of cancer diagnosis and treatment is associated with significant stress. While religion and spirituality (R/S) can provide crucial support, many patients also experience R/S distress. Screening for distress has gained recognition, with tools evolving to address spiritual needs; however, existing screening measures have limitations. This study aims to validate screening items for R/S distress among cancer patients undergoing treatment, using a standardized chaplain assessment as a reference standard.</p><p><strong>Methods: </strong>The study involved adult cancer patients undergoing outpatient treatment at Rush Cancer Center. Procedures included researcher-administered screening questions and the ONC-5 spiritual assessment interview with a board-certified chaplain. Data included demographics, illness variables, and R/S measures. Eight single-item and two multi-item screening measures were evaluated against the ONC-5. Analysis entailed descriptive statistics and sensitivity/specificity determination.</p><p><strong>Results: </strong>Study participants (N = 71) were predominantly female (53.5%) with common cancers (breast, colon/rectum, and lung). R/S distress was evident in 19.7%. Single-item screeners exhibited sensitivities from 14 to 71% and specificities from 72 to 98%. The King 2-question combination showed 71% sensitivity and 63% specificity. The Rush protocol demonstrated 36% sensitivity and 88% specificity. Post hoc analyses of two-item combinations did not enhance sensitivity.</p><p><strong>Conclusion: </strong>This study evaluated R/S distress screening items among outpatient cancer patients. The single-item screener asking whether participants' R/S provided all the strength and comfort needed now performed best with a sensitivity and specificity of 71% and 83%, respectively. Despite limitations, our findings underscore the importance of refining R/S distress screening tools in oncology care.</p>","PeriodicalId":22046,"journal":{"name":"Supportive Care in Cancer","volume":"33 3","pages":"198"},"PeriodicalIF":2.8,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Clinical pharmacist interventions on pain management in cancer patients (PharmaCAP) in low resource settings: a multicenter feasibility‑pilot randomized controlled trial.","authors":"Sunil Shrestha, Simit Sapkota, Siew Li Teoh, Bhuvan Kc, Vibhu Paudyal, Shaun Wen Huey Lee, Siew Hua Gan","doi":"10.1007/s00520-025-09249-4","DOIUrl":"https://doi.org/10.1007/s00520-025-09249-4","url":null,"abstract":"","PeriodicalId":22046,"journal":{"name":"Supportive Care in Cancer","volume":"33 3","pages":"197"},"PeriodicalIF":2.8,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143441994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fatigue in hematological cancer changes across chemotherapy trajectory within the context of IL-6, not hemoglobin level: evidence from growth curve modeling.","authors":"Hee-Ju Kim, Joon Ho Moon, Tenko Raykov","doi":"10.1007/s00520-025-09237-8","DOIUrl":"https://doi.org/10.1007/s00520-025-09237-8","url":null,"abstract":"<p><strong>Purpose: </strong>The present study aimed to examine (a) how fatigue severity changes during the course of chemotherapy in patients with hematologic cancer and (b) whether cytokines (IL-1 alpha, IL-1 beta, IL-6) are associated with fatigue change after controlling for demographic and clinical factors (e.g., hemoglobin/hematocrit, medications, comorbid conditions).</p><p><strong>Methods: </strong>This observational cohort study used data from 148 hematological cancer patients four times: prior to chemotherapy, on the last day of chemotherapy, 1 week after the chemotherapy completion, and 1 month after baseline assessment. Latent growth curve modeling was used to examine the longitudinal association of fatigue severity with cytokines and hemoglobin.</p><p><strong>Results: </strong>A quadratic growth curve model fit the data well, indicating model tenability, and explained a large amount of variance in fatigue across measurement time points. Fatigue slightly increased toward the end of chemotherapy and decreased with time after chemotherapy completion. The influence of IL-6 on fatigue was significant at all time points except at the last assessment occasion (i.e., 1 month after the baseline assessment). The influence of IL-6 on fatigue was independent (unique) from the impact of hemoglobin level. Age and chemotherapy given for the first line of treatment significantly influenced the rate of fatigue change over time. Age also influenced the change pattern's shape.</p><p><strong>Conclusions: </strong>Fatigue severity changes across the course of chemotherapy within the context of IL-6 activity, not the hemoglobin level. The influence of IL-6 may be limited during and shortly after chemotherapy. These findings inform the development of new symptom management strategies.</p>","PeriodicalId":22046,"journal":{"name":"Supportive Care in Cancer","volume":"33 3","pages":"200"},"PeriodicalIF":2.8,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143441999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Approaches to management of endocrine therapy-induced alopecia in breast cancer patients.","authors":"Michelle Nguyen, Shawna Kraft","doi":"10.1007/s00520-025-09258-3","DOIUrl":"https://doi.org/10.1007/s00520-025-09258-3","url":null,"abstract":"<p><p>Alopecia associated with use of endocrine therapy is an underreported adverse effect despite its significant impact on a patient's quality of life. There is a lack of published evidence for the treatment and management of endocrine therapy-induced alopecia (EIA). Current therapeutic strategies for EIA in breast cancer patients primarily include pharmacologic agents for androgenic alopecia given the similar underlying pathophysiology and clinical presentation of hair loss of EIA and other causes of alopecia. This review aims to summarize select prescription and non-prescription agents (i.e., over-the-counter products, nutraceuticals, dietary supplements) that may be used for EIA including general efficacy and safety. Further studies are needed in the breast cancer population to better understand the place in therapy and efficacy of these pharmacologic agents for EIA.</p>","PeriodicalId":22046,"journal":{"name":"Supportive Care in Cancer","volume":"33 3","pages":"199"},"PeriodicalIF":2.8,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143441992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unraveling the complexity of radiotherapy- and chemotherapy-induced oral mucositis: insights into pathogenesis and intervention strategies.","authors":"Yixin Jin, Jiantao Wang, Yan Wang","doi":"10.1007/s00520-025-09239-6","DOIUrl":"https://doi.org/10.1007/s00520-025-09239-6","url":null,"abstract":"<p><p>Radiotherapy- or chemotherapy-induced oral mucositis (RIOM/CIOM) presents significant challenges in cancer treatment, severely impacting patients' quality of life (QoL) and therapeutic outcomes. Despite advancements, existing prevention and treatment measures have notable limitations. RIOM/CIOM involves a multifaceted interplay of inflammatory cascades orchestrated by the innate immune response. Furthermore, dysbiosis of oral and intestinal microbiota, triggered by anticancer therapy, exacerbates mucosal damage through intricate interactions with the innate immune system. This review provides an update on pivotal signaling pathways governing the initiation and progression of RIOM/CIOM. It also elucidates the intricate relationship between microbiota dysbiosis and dysregulation of oral mucosal immune homeostasis. Moreover, potential interventions targeting these pathogenic mechanisms are summarized, offering valuable insights for further exploration of RIOM/CIOM's complex pathophysiology and the development of more effective interventions.</p>","PeriodicalId":22046,"journal":{"name":"Supportive Care in Cancer","volume":"33 3","pages":"195"},"PeriodicalIF":2.8,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of nurse-led symptom management in chronic myeloid malignancies: a randomized trial.","authors":"Maja Pedersen, Maria Torp Larsen, Brian Thomas Kornblit, Emma Ove Dahl, Kirsten Lomborg, Anders Tolver, Mary Jarden","doi":"10.1007/s00520-025-09230-1","DOIUrl":"10.1007/s00520-025-09230-1","url":null,"abstract":"<p><strong>Purpose: </strong>Chronic hematological malignancies progress slowly, potentially manifesting symptoms spanning months to years. HM-PRO is developed as a comprehensive clinical tool for assessing symptoms in hematology. The aim was to investigate the effect of a nurse-led systematic approach to symptom identification and management using HM-PRO in outpatient care in patients with chronic hematological malignancies.</p><p><strong>Methods: </strong>This is a randomized trial including 94 patients to investigate an intervention comprising (1) HM-PRO data collection, (2) HM-PRO assessment guided by an algorithm, and (3) nurse-led tailored symptom management. The control arm received standard follow-up care. The primary outcome was change in QoL. Secondary outcomes were change in prevalence of physical and psychological symptoms.</p><p><strong>Results: </strong>A statistically significant difference in QoL change scores over time favored the intervention (diff. 10.3; p = .04). For secondary endpoints, a significant between group difference in change over time for severity scores was observed in fatigue (diff. - 13.6; p = .003), overall symptom burden (diff. - 0.7 points; p = .029), emotional functioning (diff. 10.0; p < .0001), and anxiety (diff. - 2.5; p = .001).</p><p><strong>Conclusion: </strong>A 12-month nurse-led symptom management intervention within hematology significantly improved QoL, emotional functioning, fatigue, anxiety, and overall symptom burden over time. This is the first randomized trial investigating nurse-led clinical application of the HM-PRO questionnaire providing knowledge on the efficacy of systematic symptom management in clinical practice. This study highlights both the pivotal role of nurses and multidisciplinary support and the inherent value of tailored symptom management.</p><p><strong>Trial registration: </strong>Clinical trial registration number: NCT04757545 (02/12/2021).</p>","PeriodicalId":22046,"journal":{"name":"Supportive Care in Cancer","volume":"33 3","pages":"196"},"PeriodicalIF":2.8,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11829834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of cannabinoids for the prophylaxis of chemotherapy-induced nausea and vomiting-a systematic review and meta-analysis.","authors":"Ronald Chow, Anna Basu, Jagdeep Kaur, David Hui, James Im, Elizabeth Prsic, Gabriel Boldt, Michael Lock, Lawson Eng, Terry L Ng, Camilla Zimmermann, Florian Scotte","doi":"10.1007/s00520-025-09251-w","DOIUrl":"10.1007/s00520-025-09251-w","url":null,"abstract":"<p><strong>Background: </strong>Cannabinoids have potential efficacy as prophylaxis for chemotherapy-induced nausea and vomiting (CINV), but no recent meta-analysis has reported on their relative efficacy compared to other antiemetics. The aim of this meta-analysis is to examine the relative efficacy of cannabinoids for prophylaxis of CINV.</p><p><strong>Methods: </strong>A literature search was conducted in OVID Medline, EMBASE, and Cochrane Central Register of Controlled Trials from inception up until March 2024. Articles were included if they reported on complete response, no nausea, no vomiting or no use of rescue medications, and were randomized controlled trials with cannabinoids in one arm. Meta-analysis was conducted for each endpoint and for a composite endpoint amalgamating existing endpoints. Subgroup analyses by medication used in control arm and by study design were conducted. Cumulative and leave-one-out analysis was also conducted. Type I error was set at 0.05.</p><p><strong>Results: </strong>A total of 26 studies were included in this meta-analysis, of which 23 were published before the 2000s. Nearly half of the included studies had some concern for bias. Cannabinoid had superior overall CINV control compared to placebo (RR 2.65, 95% CI 1.70-4.12, I² = 0.00%). However, there was no difference between cannabinoid and active treatment alternatives (most using dated single-agent regimens) for any outcomes. A recent phase II/III trial demonstrated superior efficacy of THC:CBD for secondary prevention of CINV when used as adjunctive therapy alongside modern antiemetic regimens, albeit mostly without olanzapine.</p><p><strong>Conclusions: </strong>There is scant evidence for efficacy of cannabinoids for CINV in the era of triple and quadruple antiemetics. Although THC:CBD showed promised in a recent trial, further trials should examine its safety and efficacy in the context of regimens containing olanzapine.</p>","PeriodicalId":22046,"journal":{"name":"Supportive Care in Cancer","volume":"33 3","pages":"193"},"PeriodicalIF":2.8,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11828838/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preventive effects of progressive resistance training of different intensities on breast cancer-related lymphedema.","authors":"Zirui Zhang, Luyan Guo, Lizhi Zhou, Xijun Hao, Yijing Fan, Hong Li, Huiqian Xu, Jiwei Hu, Aijun Du, Yaqi Wang","doi":"10.1007/s00520-025-09256-5","DOIUrl":"https://doi.org/10.1007/s00520-025-09256-5","url":null,"abstract":"<p><strong>Purpose: </strong>Explore the preventive effects of varying intensity progressive resistance exercise on breast cancer-related lymphedema.</p><p><strong>Methods: </strong>A total of 114 breast cancer patients who underwent axillary lymph node dissection at Tangshan People's Hospital from January to April 2024 were included. Participants were randomly assigned to three groups: the control group received conventional care; intervention group 1 received conventional care + low-intensity progressive resistance exercise; and intervention group 2 received routine nursing + moderate and high-intensity progressive resistance exercise. Body composition and grip strength were assessed pre-intervention, post-intervention, and at 3 and 6 months follow-up to compare differences among the groups.</p><p><strong>Results: </strong>(1) Body composition: At post-intervention, 3 and 6 months follow-up, segmental water differences and extracellular water ratios, along with 1- and 5-kHz SFBIA in both intervention groups, were lower than in the control group. Intervention group 2 had a lower extracellular water ratio than group 1 at post-intervention, and at 3 months follow-up, group 2 showed lower water differences and extracellular water ratios than group 1, with slight variations at 6 months (P < 0.001). (2) Grip strength: At post-intervention, 3 months and 6 months follow-up, grip strength in intervention group 1 and intervention group 2 was higher than that in control group, and the difference was statistically significant (P < 0.001).</p><p><strong>Conclusion: </strong>Resistance exercise enhances muscle strength and prevents lymphedema, with moderate-high-intensity exercise proving more effective than low intensity. Adverse events were minimal, suggesting that increasing resistance exercise intensity, while considering participants' conditions, may yield better preventive outcomes.</p>","PeriodicalId":22046,"journal":{"name":"Supportive Care in Cancer","volume":"33 3","pages":"194"},"PeriodicalIF":2.8,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}